Compare · BSX vs IVF
BSX vs IVF
Side-by-side comparison of Boston Scientific Corporation (BSX) and INVO Fertility Inc. (IVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and IVF operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 23523.1x IVF ($2.7M).
- Over the past year, BSX is down 54.6% and IVF is down 99.0% - BSX leads by 44.4 points.
- BSX has been more active in the news (5 items in the past 4 weeks vs 2 for IVF).
- BSX has more recent analyst coverage (25 ratings vs 0 for IVF).
- Company
- Boston Scientific Corporation
- INVO Fertility Inc.
- Price
- $44.38+0.50%
- $0.56+1.27%
- Market cap
- $63.97B
- $2.7M
- 1M return
- +1.88%
- -41.31%
- 1Y return
- -54.61%
- -99.01%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest IVF
- Amendment: SEC Form SCHEDULE 13G/A filed by INVO Fertility Inc.
- INVO Fertility to Participate in the Lytham Partners Fall 2026 Investor Conference
- SEC Form S-8 filed by INVO Fertility Inc.
- INVO Fertility Inc. filed SEC Form 8-K: Regulation FD Disclosure
- INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
- INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International
- INVO Fertility Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
- SEC Form 10-Q filed by INVO Fertility Inc.
- SEC Form 424B3 filed by INVO Fertility Inc.